CIK 0001640266 · Accelerated filer<br>Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-09 | PFREUNDSCHUH PETER P. Chief Financial Officer | Grant or award | +30,000 | 179,433 | ||
| 2024-02-09 | PFREUNDSCHUH PETER P. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2024-01-17 | Swartz Robin Chief Operating Officer | Sale | −2,543 | $7.15 | $18K | 72,327 |
| 2024-01-17 | Carter Todd Alfred Chief Scientific Officer | Sale | −1,266 | $7.18 | $9K | 53,094 |
| 2023-10-03 | PFREUNDSCHUH PETER P. Chief Financial Officer | Sale | −13,567 | $6.99 | $95K | 149,433 |
| 2023-10-01 | Fahey Sandell Jacquelyn Chief Legal Officer | Grant or award | +61,000 | 61,000 | ||
| 2023-09-15 | Carter Todd Alfred Chief Scientific Officer | Option exercise 10b5-1 | +5,000 | $2.85 | $14K | 64,860 |
| 2023-09-15 | Carter Todd Alfred Chief Scientific Officer | Sale 10b5-1 | −10,500 | $8.16 | $86K | 54,360 |
| 2023-09-15 | Carter Todd Alfred Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 40,000 | ||
| 2023-07-10 | Fahey Sandell Jacquelyn Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +122,000 | 122,000 | ||
| 2023-07-06 | Carter Todd Alfred Chief Scientific Officer | Sale 10b5-1 | −5,500 | $10.80 | $59K | 59,860 |
| 2023-06-30 | Carter Todd Alfred Chief Scientific Officer | Option exercise 10b5-1 | +5,000 | $2.85 | $14K | 70,360 |
| 2023-06-30 | Carter Todd Alfred Chief Scientific Officer | Sale 10b5-1 | −5,000 | $11.41 | $57K | 65,360 |
| 2023-06-30 | Carter Todd Alfred Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 45,000 | ||
| 2023-06-06 | PIERCE GLENN Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2023-06-06 | MACKEY CATHERINE J Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2023-06-06 | Vitale Nancy Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2023-06-06 | Onyia Jude Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2023-06-06 | Higgins Michael J Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2023-06-06 | Colon Grace Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 |
Page 6 of 7 · 130 trades